An ordinal ranking system for clinically grading disability due to chronic asthma is described, by which to quantitate the changing course of individual patients during time-sequence observations. Experience over two years with 47 asthmatic patients undergoing various trials of disodium cromoglycate therapy indicates this index is very sensitive, reasonably reproducible in the hands of clinicians trained in its use, and specific for asthma rather than for coexisting chronic obstructive lung disease in this patient population. Duplicate scoring by trained observers is recommended. Correlations between disability and daily asthma symptom scores were generally statistically significant, but coefficients were low. Correlations of disability with pulmonary function parameters (measured fortnightly) were not significant. Statistically significant improvement was evident in most asthma indices after a month of disodium cromoglycate treatment. Disability scores improved a great deal, which implies that the observed "statistically significant" improvement in the asthma patient after disodium cromoglycate treatment represents a real clinical advantage.
Chroni c bronchial asthma is often associated with disability of varying severity. For many patients, the presence or absence of disability outweighs all other specific symptoms or physical signs of disease, for it constitutes the critical discriminating feature between their idea of "illness" and "health." Physicians and surgeons also use disability very often as a major index of the success or failure of therapy, or as the basis for tactical decisions such as hospitalization or surgery. ' It is surprising therefore that disability has received little attention in formal clinical studies of asthma. For example, several reviews of the many clinical trials of a new drug for chronic asthma, disodium cromoglycate (DSCG) make no mention of it.48 Some of the studies reviewed did in fact use various indices to express, at least in part, chronic asthma disability,9'4 or work capacity.'569 Other more heterogeneous indices combining a disability component with various asthma symptoms have also been used.9" 2#{176} In other studies, asthma disability has been examined indirectly,2' assuming an unproved relationship to Symptom or pulmonary function parameters or indefinitely and incompletely,'4'2228 or not at all. 2933 It is unfortunate that this is so, because disability would appear to offer a very useful "benchmark" against which to compare the efficacy of various forms of asthma treatment. Certainly no other universally applicable standard reference scale by which to quantify clinically important variations in asthma severity has yet been evolved. Witness the wide range of opinions, typified by the diametrically opposed claims of several expert clinical observers, about the clinical significance, or lack of it, of the statistically significant improvement observed in various asthma indices during the above-mentioned #{176}Outside North America, "disability" is sometimes used synonymously with "inipairment,"'#{176}. Pima facie, physicians could probably agree that any degree of reduction in asthma disability could be arbitrarily designated as"clinically valuable," and that conversion to the nondisabled state should be a primary goal of treatment. The problem then becomes one of defining asthma disability and measuring it. Some authorities34 reject both the feasibility and the necessity of a medical estimate of disability, but this seems inconsistent with the rehabilitative goals of the clinician dealing with chronic pulmonary disease.
Disability grading systems have l)een developed for various chronic pulmonary diseases other than asthma, such as cystic fibrosis,35-38 byssinosis,39'4#{176} chronic obstructive lung disease (COLD) 4041 They apparently have clinical value, although their reliability is not well documented, and observer error is undoubtedly significant.35-39 But these indices can not be directly applied to chronic asthma for they are not designed to take cognizance of the paroxysmal and nonexertional component of the latter, and some are derived in part from clinical or laboratory variables which are irrelevant in most asthmatic patients.35'36 The system of the AMA Committee on Rating of Physical Impairment is inapplicable, for it is designed to rate impairment rather than disability.42 Current North American usage distinguishes "impairment" (of organ function (from "disability," which represents one of the remote effects of impairment on the organism.34'4244#{176}
Tests of pulmonary function are relevant to respiratory disability, and are more reproducible and error-free than clinically derived subjective indices, but factors other than pulmonary function impairment have been shown to be more important determinants of disability: socioeconomic status and educational job requirements,2'3'43 and probably occupation and regional air pollution. 46 Various tests of work capacity, both objective 9 and nonobjective,50 yield useful data of considerable relevance, but work capacity is not entirely synonymous with disability. Also Gaensler et a143 emphasize the dependence of these tests on patient motivation, and their limited ability to reflect the respiratory distress associated with a patient's customary work outside the test laboratory.
With the foregoing considerations in mind, we elected to rate disability in chronic asthma patients in clinical terms, independent from pulmonary function impairment, and to express it as an Asthma Disability Score (ADS). This ADS closely resembles the U.S. National Health Survey datum "restricted activity days,"5' but is a little more refined because it provides more categories at the lower levels of disability. This clinical rating is based on a formulation of disability as the difference between work capacity and work demand imposed by an individual asthmatic patient's accustomed activities.
This seems consistent with the relevant physiologic principles, and some clinical and epidemiologic usages.34'43'44'5' It appears synonymous with "impediment,"53 and analogous to the concept of "insufficiency" of an organ systenl.* Asthma disability, thus defined and measured by ADS is a special sub-set of "clinical disability"o and is not synonymous with "pulmonary functional impairment class,"43 although the latter includes disability as one of its components. Neither is it synonymous with "unemployed," "ability to work,"5#{176} "work capacity,"47 "whole man impairment,"42 "functional estimation,"57 "exercise tolerance,"58 or "treadmill performance."59 We describe herewith some experience with this index, which has, in our hands, been a sensitive indicator of change in the course of chronic asthma; has been reliable when observer error is carefully controlled; and which we have found to specifically correlate with bronchial asthma independent of associated diseases such as chronic obstructive lung disease.
METHODS
Disability was rated on a six-point ordinal ranking scale 
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A variety of other asthma indices were derived from 5 6 patients' current daily symptom diaries and fortnightly pu'1-monary function tests. These arelisted in Table 2 and have been further described elsewhere.60'61 A commonly used dlyspnea grading system41'12 was paraphrased for use by an asthmaticpopulation, and the resulting score was termed a "daily breathlessness score" (DBS). Thirty-one patients were treated with DSCG and ol)Serve(l for 12 weeks in 1969 in a "double-blind," placebo-controlled, crossover-design, clinical study, which is follydescribed elsewhere.60'6' Twenty-nine patients were treated for 16 weeks in the following year, 14 of whom had also been treated in 1969. All patients, after pretreatment recording of all indices, inhaled 20 mg of DSCG (without isoproterenol)
four tunes daily, in addition to continuing their regular antiasthma medications, Scores for each index after four weeks' treatment are termed "treated" values. The basis for allanalyses examining for treatment effect was the observed "within-subject" difference between pretreatment and treatedvalues for each index separately. Between-subject and between-group analyses were not used because of our experience with the practical difficulties of pretreatment matching of asthma patients in terms of the indices monitored (including ADS). Even with very careful preliminary matching, uncontrollable between-subject variation can totally 01)-score a therapeutic effect that is readily demonstrable by "within-subject" analyses.60 '6' Standard statistical methods of correlation analysis and significance testing were used. Differences between pretreatment and treated values were judged statistically significant if p = <0.05, with paired "t" and Wilcoxon's sign rank test, Both tests were used, because, in preliminary analysis, not all theindices couldbe shosvntobe normally distributed,60
RESULTS
In Table 3 the consistency between the three The population studied comprised 47 ambulatory outpatients with typical clinical findings of chronic asthma, and with objectiveevidence of air\vay obstruction. Most were mildly disabled by asthma (Fig 1) , and therefore suitable subjects for examination of this particular aspect of the chronic asthma syndrome. These initial disability scores represent the residual, after considerable previous treatment by conventional asthma therapy. In each patient, the disease had been under the personal observation and management of the present writers (JUT and l)McC) for'! to 18 years (median: nine years).A more detailedcharacterization of the group has been published elsewhere.60M They were free of clinically recognizable emphysema or lung fibrosis. But about tsvo-thirds of them had some coexisting COLD as determined by the limitedreversibility of theirairway obstruction, in spite of aggressive corticosteroid and bronchodilator treatuncut. This typically comprised two to four weeks of four ephedrine compound or theophylline doses daily, plus 40 to 60 mg of prednisone daily per os, and epinephrine or intravenously administered steroids when necessary to establish thelimits of"re ersibility" oftheobservedabnormal MMFR's. By standard questionnairecriteria"many had chronic l)ronchitis, Significant disability of nonpuulmonary origin was excluded ________________________________________________________ clinically aswas thatdt,eto"extrinsic residuals," as described by Daitz.44 In three or four patients, other impairment components such as musculoskeletal or psychologic were accepted, because their contribution to the disability could be easily differentiated from the asthma component. controlled study of cromolyn sodium sponsored by the Drug Committee of the American Academy of Allergy." The longterm prophylaxis of chronic asthma in children using cromolyn sodium by different parameters was demonstrated as effective in a previous study reported by us. '9 There is an ethical problem of maintaining asthmatics on placebo medication for prolonged periods. However, a recent publication by Silverman and associates2#{176} does describe a one year placebo controlled cromolyn study. In their report, the placebo group were not given a true placebo at all, but isoproterenol sulfate 0.1 mg, while the treatment group received cromolyn sodium plus isoproterenol sulfate 0.1 mg (Intal compound). The results indicated an unequivocal difference between the two groups, with 71 percent of the treatment group being well controlled after one year while 76 percent of the placebo group had dropped out because of inadequate control of manifestations.
In this report, of the measures used for assessing the longterm therapeutic efficacy of cromolyn, the most useful were clinical disability levels, including exercise intolerance, school absenteeism, frequency of hospitalizations, and interference with sleep.2' However, such records were greatly influenced by the presence of aggravating factors, for example, persistence of poor environmental control techniques which included keeping of pets with fur.22
In addition, simple pulmonary function tests performed at each patient visit were important. Persistent stimulation by immune and nonimmune factors contributes to abnormal levels of airways caliber.23
In our opinion these factors make possible the classification of chronic asthma by PEFR into normals, variables, and abnormals (Fig 1) . Another relatively objective and useful measure of the asthmatic state, so long as the patient was taking required as needed doses, was that of concomitant bronchodilator medication. Such medication flay be used frequently in some children to maintain a symptom-free state, whereas in other patients, moderate symptoms are well tolerated and bronchodilator doses are reduced or eliminated.
The time of onset of effectiveness of cromolyn therapy differs, and depends on the type of chronic asthma being treated.'8"9 Occasionally, it seems to take nearly a month before a definite drug effect is manifest. Predictable seasonal asthma, however, often responds to cromolyn in 4 to 14 days or less and, frequently, concomitant use of bronchodilators can be reduced or withdrawn in three to six weeks. For perennial and unresponsive asthma, round-theclock bronchodilators and alternate day low-dose corticosteroids often can be decreased or withdra m in three to five months. Considering the attendant risks of unpredictable crises, patients must be warned that low-dose maintenance of 5 to 12.5 mg prednisone or equivalent on alternate days is better than none. Not infrequently, adequate doses of bronchodilators are needed for the best cromolyn effect. tm9 Cromolyn should not be given to uncooperative patients, nor during status asthmaticus, nor during moderate or severe bronchial infections. Unresponsive are children with aspirin intolerance and early onset asthma with egg albumin sensitive eczema.
Children may develop strong psychologic dependence on cromolyn after a few weeks of treatment because attempts to discontinue the drug reduce their physical activities, and inadvertent exposures to increased allergen will further increase their discomfort. This becomes apparent in patients when a dose or two has been inadvertently or deliberately missed. For most, maximal effectiveness of a single 20 mg dose of cromolyn lasts four to six hours. Children with chronic asthma take and tolerate round-the-clock bronchodilators for months and years. Likewise prophylactic cromolyn use is not objected to by these patients.24
In selecting patients for cro,iiolyn prophylaxis, we have found the following guidelines helpful: patients in whom round-the-clock theophylline therapy is only effective in doses continuously in excess of 12 mg/kg/day by all routes;24 when repeated shortterm corticosteroids are required to control the asthma; patients who do not respond adequately to conventional therapy; and when the peak expiratory flow rates frequently or consistently fall below 80 percent of predicted normal for sex and height. The main contributions of cromolyn to the study and adju,ictive treatment of asthma and allergy are: the prevention of experimentally induced bronchial obstruction by pretreatment with this drug and the prevention of asthma in patients acutely sensitive to inhalants, when exposure is unavoidable; the significant lessening of manifestations and improved exercise tolerance of patients with chronic asthma and the decreased need for bronchodilators and corticosteroids following regular daily inhalations of cromolyn; and the use of the drug as a tool in the study of immunologic mechanisms of respiratory disease, particularly thoseinvolving typeI (reaginmediated)and type III(precipitin-mediated) a!-lergic reactions.
ACKNOWLEDGMENT:
We are indebted to Robert Stiratelli, MS. and Mr. Cedric Grigg for assistance in processing the data.
Frank Lloyd Wright (1869-1959) on Architecture
As man-the savage-emerged from the natural cave to l)uild one of his own, origins of the history ofarchitec- 
